SOD1 and metabolic dysfunction-associated steatohepatitis: Notably, cotreatment with MCD-CME maintained or even enhanced both Nrf2 activation and SOD expression, suggesting a potential therapeutic benefit in mitigating oxidative stress in patients with NASH.